NCT02588131UnknownPhase 2
A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1
Italian Network for Tumor Biotherapy Foundation1 site in 1 country40 target enrollmentStarted: October 2015Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- immune-related (ir)- objective response rate (ORR)
Study Overview
Brief Summary
This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma subjects
Detailed Description
The prognosis of malignant mesothelioma (MM) patients remains dismal and effective treatment represents a high un-met medical need. Investigators have recently reported promising clinical activity of the anti-CTLA-4 mAb tremelimumab in pre-treated MM patients: disease control rate (DCR) was 31%, and survival rate at 1- and 2-years were 48.3% and 36.7%, respectively. These initial findings were corroborated by a second study in which, based on retrospective pharmacokinetic analyses, an intensified schedule of tremelimumab was utilized. Fifty-two % of patients achieved a DCR (median duration 10.9 months). These intriguing clinical results and the emerging efficacy of immunomodulatory mAb targeting the PD-1/PD-L1 axis in different tumor types, prompted us to design the NIBIT-MESO-1 study aimed to investigate the efficacy of tremelimumab combined with the anti-PD-L1 MEDI4736 in MM patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Willing and able to give written informed consent.
- •Histologic diagnosis of malignant mesothelioma.
- •Subjects who have refused a first line platinum-based chemotherapy, or subjects in progression of disease after a maximum of one line of platinum-based therapy for advanced disease.
- •Disease not amenable to curative surgery.
- •Measurable disease, per modified Response Evaluation Criteria in Solid Tumor [RECIST] for pleural mesothelioma or RECIST version 1.1 for peritoneal mesothelioma).
- •Life expectancy ≥ 12 weeks.
- •ECOG performance status of 0 or 1
- •Normal laboratory tests
- •Negative screening tests for HIV, Hepatitis B, and Hepatitis C.
- •Availability of archival tumor tissue or feasibility to perform a new tumor biopsy at screening phase.
- •Men and women, of and over 18 years old. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 180 days after the last dose of investigational drug.
Exclusion Criteria
- •Involvement in the planning and/or conduct of the study.
- •Participation in another clinical study with an investigational product during the last 6 weeks.
- •Any previous treatment with a CTLA4, PD-1 or PD-L1 inhibitor, including tremelimumab or MEDI
- •History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study drug and of low potential risk for recurrence. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ.
- •Receipt of the last dose of anti-cancer therapy ≤ 6 weeks prior to the first dose of study drug.
- •Mean QT interval corrected for heart rate (QTc) ≥470 ms using Bazett's Correction.
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of tremelimumab and MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •Any unresolved toxicity (CTCAE grade >2) from previous anti-cancer therapy.
- •Any prior Grade >3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade
- •Active or prior documented autoimmune or inflammatory disorders
- •History of primary immunodeficiency or allogeneic organ transplant.
- •History of hypersensitivity to tremelimumab or MEDI4736 or any excipient.
- •Uncontrolled intercurrent illness including, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses
- •Known history of previous clinical diagnosis of tuberculosis.
- •History of leptomeningeal carcinomatosis.
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving tremelimumab and MEDI
- •Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids.
- •Subjects with uncontrolled seizures.
Arms & Interventions
tremelimumab plus MEDI4736
Experimental
Tremelimumab in combination with MEDI4736
Intervention: tremelimumab plus MEDI4736 (Drug)
Outcomes
Primary Outcomes
immune-related (ir)- objective response rate (ORR)
Time Frame: 60 weeks
proportion of subjects with complete response \[CR\] or partial Response \[PR\]) according to the ir-modified-RECIST or ir-RECIST 1.1 in pleural or peritoneal subjects, respectively.
Secondary Outcomes
- Immune-related-progression-free-survival (PFS)(60 weeks)
- Safety (adverse events)(120 weeks)
- Immune-related-ORR based on PD-L1 tumor expression(60 weeks)
- Immune-related-Disease control rate (ir-DCR)(60 weeks)
- Immune-related-progression- free-survival based on PD-L1 tumor expression(60 weeks)
- Overall survival based on PD-L1 tumor expression(120 weeks)
- Disease control rate (DCR)(60 weeks)
- Immune-related-Disease control rate based on PD-L1 tumor expression(60 weeks)
- progression-free-survival (PFS)(60 weeks)
- Overall survival (OS)(120 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
A Clinical Study With Tremelimumab as Monotherapy in Malignant MesotheliomaMalignant MesotheliomaNCT01649024Azienda Ospedaliera Universitaria Senese29
Completed
Phase 2
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial CancerUrothelial CarcinomaNCT03557918Matthew Galsky26
Active, not recruiting
Phase 2
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialNeoadjuvantImmunotherapySarcoma,Soft TissueRadiation TherapyNCT06128863Maria Sklodowska-Curie National Research Institute of Oncology40
Unknown
Phase 2
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Potentially Resectable Locally Advanced Malignant Tumors of Biliary SystemNCT05036798Tianjin Medical University Cancer Institute and Hospital30
Completed
Phase 2
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesAdvanced and/or Metastatic SarcomaNCT02815995M.D. Anderson Cancer Center57